<DOC>
	<DOCNO>NCT02452528</DOCNO>
	<brief_summary>Patients chronic Hepatitis B Virus ( HBV ) infection receive multiple dos ARC-520 combination entecavir tenofovir evaluate safety efficacy .</brief_summary>
	<brief_title>Study ARC-520 Patients With HBeAg ( Hepatitis B e Antigen ) Positive Chronic Hepatitis B Virus</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , placebo-controlled , multi-dose study ARC-520 combination entecavir tenofovir administer patient HBeAg positive immune active chronic HBV infection , receive ongoing entecavir tenofovir therapy . Patients sign Institutional Review Board/Ethics Committee-approved informed consent , meet protocol eligibility criterion continue receive daily oral entecavir ( 0.5-1.0 mg/day ) daily oral tenofovir ( 300 mg/day ) either ARC-520 1.0 mg/kg placebo 3 total dos administer every four week . Patients undergo following evaluation regular interval study : medical history , physical examination , vital sign measurement ( blood pressure , heart rate , respiratory rate , temperature ) , weight , adverse event assessment ( AEs ) , echocardiograms , 12-lead ECGs , liver fibrosis testing , concomitant medication assessment , blood sample collection hematology , coagulation , chemistry , Pharmacokinetic ( PK ) exploratory Pharmacodynamic ( PD ) measure , HBV serology , Follicle Stimulating Hormone ( FSH ) test ( post-menopausal female ) pregnancy test female childbearing potential . Patients monitor total 21 week . Clinically significant change include AEs follow resolution , condition stabilizes , event otherwise explain , patient lose follow-up .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Male female , 18 75 year age Written inform consent Body mass index ( BMI ) 17.5 30.0 kg/m2 No clinically significant abnormality screening/predose 12lead ECG assessment No abnormal find clinical relevance Diagnosis HBeAg positive , immune active , chronic HBV infection &gt; 2 month continuous treatment daily oral entecavir tenofovir Must use 2 effective method contraception ( double barrier contraception hormonal contraceptive along barrier contraceptive ) Pregnant lactate Acute sign hepatitis/other infection within 4 week screen Hepatic transaminase ( ALT AST ) &gt; 3 time upper limit normal Liver Elastography ( i.e . FibroScanÂ® ) score &gt; 9 Antiviral therapy entecavir tenofovir within 3 month screen Prior treatment interferon last 3 year Use anticoagulant , corticosteroid , immunomodulators , immunosuppressant within 6 month screen Use within 7 day prior screen dietary and/or herbal supplement interfere liver metabolism Use drug know induce inhibit hepatic drug metabolism within 30 day study drug administration Use prescription medication within 14 day prior study drug administration Depot injection/implant drug except birth control within 3 month prior study drug administration Known diagnosis diabetes mellitus History autoimmune disease Human immunodeficiency virus ( HIV ) infection Seropositive Hepatitis C Virus ( HCV ) , and/or history delta virus hepatitis Hypertension ; blood pressure &gt; 150/100 mmHg History cardiac rhythm disturbance Family history congenital long QT syndrome , Brugada syndrome unexplained sudden cardiac death Symptomatic heart failure , unstable angina , myocardial infarction , severe cardiovascular disease within 6 month prior study entry History malignancy , except adequately treat basal cell carcinoma , squamous cell skin cancer , superficial bladder tumor , situ cervical cancer Major surgery within 3 month screen History alcohol and/or drug abuse &lt; 12 month screen Regular use alcohol within 6 month ( ie , 14 unit alcohol per week ) Evidence systemic acute inflammation , sepsis , hemolysis Diagnosed significant psychiatric disorder Use drug abuse History allergy bee venom Positive reaction bee venom allergy immunoglobulin E ( IgE ) test Use investigational agent device within 30 day Clinically significant inherit acquire gastrointestinal pathology , unresolved gastrointestinal symptom , liver kidney disease Presence cholangitis , cholecystitis , cholestasis , duct obstruction Clinically significant history presence uncontrolled systemic disease Donated loss whole blood 50 milliliter ( mL ) 499 mL within 30 day 499 mL 31 56 day prior study treatment History fever within 2 week screen Immunization/planned immunization live attenuate vaccine except influenza vaccine Presence medical psychiatric condition social situation impact compliance result additional safety risk Excessive exercise/physical activity within 7 day screening/enrolment study History coagulopathy/stroke within past 6 month , and/or concurrent anticoagulant medication ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>HBV</keyword>
</DOC>